This ICR collects information from
dietary supplement and non-prescription drug manufacturers and
distributers seeking to introduce these products into interstate
commerce under the FFDCA. Respondents provide the agency with
proposed labeling for their products as required under the
applicable statutes and FDA clears the labeling to ensure
compliance so the products can be marketed. Products that do not
comply with the applicable labeling regulations may be misbranded
and subject to enforcement action.
FDA is requesting to extend
approval of the ICR, for which there is a decrease in burden. The
burden change is due to an adjustment based on the agency's
determination that the number of disclosures per respondent, the
total annual number of disclosures, the average burden per
disclosure, and the total annual hour burden have decreased.
$0
No
No
No
No
No
Uncollected
Domini Bean 301 796-5733
domini.bean@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.